AstraZeneca PLC AZN Director/PDMR Shareholding

  AstraZeneca PLC (AZN) - Director/PDMR Shareholding

RNS Number : 7579P
AstraZeneca PLC
29 October 2012

Transactions by Person Discharging Managerial Responsibilities

Disclosure Rules DR 3.1.4R

On 26 October 2012, Pascal Soriot, Chief Executive Officer, was granted awards
over the Company's USD0.25 Ordinary Shares as set out below. These share
awards were negotiated and agreed at the time of Mr Soriot's appointment as
Chief Executive Officer of the Company and were approved by the Remuneration
Committee in order to compensate Mr Soriot for the forfeiture of unvested
long-term incentive awards from his previous employer. The principle
governing the decision of the Remuneration Committee was that the buyout
should be implemented only in shares of AstraZeneca in circumstances where the
vesting and, in the case of the AZIP award, holding period operate over a
period of many years.

On 26 October 2012, Mr Soriot was granted an award under the terms of the
AstraZeneca Investment Plan (AZIP) over the Company's USD0.25 Ordinary Shares
as follows:

Shares awarded Award price

under AZIP

69,108         2894p

This AZIP award is subject to a four-year performance period (1 January 2012
to 31 December 2015) and a subsequent four-year holding period (1 January 2016
to 31 December 2019). The performance hurdle that applies to this AZIP award
is that the annual dividend per share paid to holders of Ordinary Shares must
increase from $2.80 over the four-year performance period ($2.80 being the
full-year dividend for 2011), and that dividend cover over the same period
(based on reported earnings before restructuring costs) does not fall below
1.5 times.

A summary of the AZIP can be found in the AstraZeneca Annual Report and Form
20-F Information 2011 which is available on the Company's website

Also on 26 October 2012, Mr Soriot was granted an award of restricted shares
as follows:

Restricted shares awarded Award price

69,108                    2894p

Mr Soriot's employment with the Company commenced on 1 October 2012 and the
restricted shares will vest, subject to his continued employment with the
Company, as follows:

40% will vest on 1 October 2013

30% will vest on 1 October 2014

30% will vest on 1 October 2015

Following these awards, Mr Soriot has a total interest in 138,216 AstraZeneca

A C N Kemp

Company Secretary

29 October 2012

                     This information is provided by RNS
           The company news service from the London Stock Exchange


RDSUKSURUBARUAA -0- Oct/29/2012 13:10 GMT
Press spacebar to pause and continue. Press esc to stop.